Updated Guidance on Metabolic Dysfunction–Associated Liver Disease

Metabolic dysfunction–associated steatotic liver disease (MASLD) is increasingly diagnosed and managed in primary care settings, thanks to rapid improvements in noninvasive tests for fibrosis and the recent approval of semaglutide and resmetirom for treatment. In response to these changes, a multidisciplinary international panel has released updated consensus recommendations on MASLD; their work was partially supported by companies that manufacture resmetirom and MASLD diagnostic tests.* Both the panel and the American Diabetes Association…